Can CM272, a dual G9a/DNMT1 inhibitor, be used as an immunomodulating agent to enhance the efficacy of existing immunotherapies in melanoma?

Lien De Beck; Filipe Prosper; Ken Maes; Karin Vanderkerken; Karine Breckpot

Can CM272, a dual G9a/DNMT1 inhibitor, be used as an immunomodulating agent to enhance the efficacy of existing immunotherapies in melanoma?

Lien De Beck, Filipe Prosper, Ken Maes, Karin Vanderkerken, Karine Breckpot

Research output: Unpublished contribution to conference › Poster

53 Downloads (Pure)

Original language	English
Publication status	Unpublished - 2019
Event	BACR: novel combination strategies for cancer treatment - Antwerp, Belgium Duration: 1 Feb 2019 → …

Conference

Conference	BACR: novel combination strategies for cancer treatment
Country/Territory	Belgium
City	Antwerp
Period	1/02/19 → …

Access to Document

Poster Lien De Beck BACR 20190201Final published version, 787 KB

Handle.net

Persistent link

Cite this

@conference{08f477bc34da405e954f03fb23512a56,

title = "Can CM272, a dual G9a/DNMT1 inhibitor, be used as an immunomodulating agent to enhance the efficacy of existing immunotherapies in melanoma?",

author = "{De Beck}, Lien and Filipe Prosper and Ken Maes and Karin Vanderkerken and Karine Breckpot",

year = "2019",

language = "English",

note = "BACR: novel combination strategies for cancer treatment ; Conference date: 01-02-2019",